4
Changes in Ownership
Beam Therapeutics Inc. Filed Acc 0001193125-26-292526
CEO sold 50,000 shares at an average $34.90 ($1,745,037)
- CEO acquired 50,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Evans John M. CEO | 2026-06-29 | Option exercise 10b5-1 | +18,663 | $0.67 | $12,504 | 1,065,868 | D: show line 1 in the form |
| Evans John M. CEO | 2026-06-29 | Option exercise 10b5-1 | +6,337 | $1.03 | $6,527 | 1,072,205 | D: show line 2 in the form |
| Evans John M. CEO | 2026-06-29 | Sale 10b5-1 | −13,421 | $35.13 | $471,528 | 1,058,784 | D: show line 3 in the form |
| Evans John M. CEO | 2026-06-29 | Sale 10b5-1 | −11,579 | $35.91 | $415,824 | 1,047,205 | D: show line 4 in the form |
| Evans John M. CEO | 2026-06-30 | Option exercise 10b5-1 | +25,000 | $1.03 | $25,750 | 1,072,205 | D: show line 5 in the form |
| Evans John M. CEO | 2026-06-30 | Sale 10b5-1 | −23,100 | $34.26 | $791,482 | 1,049,105 | D: show line 6 in the form |
| Evans John M. CEO | 2026-06-30 | Sale 10b5-1 | −1,900 | $34.84 | $66,203 | 1,047,205 | D: show line 7 in the form |
| Open-market sales · 50,000 sh · avg $34.90 · $1,745,037 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Evans John M. CEO | 2026-06-29 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,663 | 9 | D: show line 8 in the form | |||||
| Evans John M. CEO | 2026-06-29 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,337 | 230,804 | D: show line 9 in the form | |||||
| Evans John M. CEO | 2026-06-30 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 205,804 | D: show line 10 in the form |
Loading xslF345X06/ownership.xml…